These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 25732167

  • 1. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
    J Clin Oncol; 2015 Apr 10; 33(11):1243-51. PubMed ID: 25732167
    [Abstract] [Full Text] [Related]

  • 2. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.
    Int J Cancer; 2016 Dec 15; 139(12):2698-2704. PubMed ID: 27557616
    [Abstract] [Full Text] [Related]

  • 3. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.
    Eur Urol; 2015 Sep 15; 68(3):386-96. PubMed ID: 25484142
    [Abstract] [Full Text] [Related]

  • 4. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
    Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.
    Eur Urol; 2017 Dec 15; 72(6):920-928. PubMed ID: 28711383
    [Abstract] [Full Text] [Related]

  • 5. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.
    BJU Int; 2016 Sep 15; 118(3):391-8. PubMed ID: 26497726
    [Abstract] [Full Text] [Related]

  • 6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr 15; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

  • 7. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
    Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.
    Eur Urol; 2012 Jun 15; 61(6):1119-28. PubMed ID: 22336376
    [Abstract] [Full Text] [Related]

  • 8. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL, O'Malley AJ, Smith MR.
    J Clin Oncol; 2006 Sep 20; 24(27):4448-56. PubMed ID: 16983113
    [Abstract] [Full Text] [Related]

  • 9. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 10. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
    Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S.
    Eur Urol; 2011 Dec 17; 60(6):1244-50. PubMed ID: 21908097
    [Abstract] [Full Text] [Related]

  • 11. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S.
    Prostate Cancer Prostatic Dis; 2018 Nov 17; 21(4):451-460. PubMed ID: 29988099
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.
    JAMA Oncol; 2016 Apr 17; 2(4):500-7. PubMed ID: 26720632
    [Abstract] [Full Text] [Related]

  • 13. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL, O'Malley AJ, Freedland SJ, Smith MR.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):39-46. PubMed ID: 19996060
    [Abstract] [Full Text] [Related]

  • 14. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
    Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J.
    Eur Urol; 2012 Apr 06; 61(4):690-700. PubMed ID: 21945719
    [Abstract] [Full Text] [Related]

  • 15. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.
    Eur Urol; 2016 Jul 06; 70(1):56-61. PubMed ID: 26138040
    [Abstract] [Full Text] [Related]

  • 16. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Jespersen CG, Nørgaard M, Borre M.
    Eur Urol; 2014 Apr 06; 65(4):704-9. PubMed ID: 23433805
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.
    Eur Urol; 2014 Dec 06; 66(6):1125-32. PubMed ID: 24495466
    [Abstract] [Full Text] [Related]

  • 18. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.
    Osteoporos Int; 2015 Sep 06; 26(9):2281-90. PubMed ID: 25990353
    [Abstract] [Full Text] [Related]

  • 19. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.
    Eur J Cancer; 2017 May 06; 77():99-108. PubMed ID: 28390298
    [Abstract] [Full Text] [Related]

  • 20. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
    Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J.
    Eur J Cancer; 2012 Jul 06; 48(11):1672-81. PubMed ID: 22386317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.